Lanreotid Zentiva

Lanreotide, the active ingredient in Lanreotid Zentiva, is a somatostatin analog presented as an injectable solution for subcutaneous use. It treats acromegaly and hormone‑secreting neuroendocrine tumors in adult patients, helping to control excess growth hormone and related symptoms.

GNH USA supplies Lanreotid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The product is manufactured under EU GMP standards and is distributed to meet the needs of specialist care units across multiple continents globally.

Lanreotide is employed in disorders driven by excess growth hormone secretion or hormone‑producing neuroendocrine tumors. - Acromegaly: lowers serum growth hormone and IGF‑1 levels, reducing disease activity. - Carcinoid syndrome (functional neuroendocrine tumors): diminishes flushing and diarrhoea by suppressing hormone release. - Gastroenteropancreatic neuroendocrine tumors: controls hormone‑related symptoms and may slow tumor progression.

Lanreotide may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Injection site pain: mild discomfort or erythema at the injection site. - Diarrhoea: loose stools occurring shortly after dosing. - Nausea: transient feeling of sickness. - Abdominal pain: cramping or discomfort in the abdomen. - Headache: mild to moderate head pain. - Hyperglycaemia: elevated blood glucose levels, especially in diabetic patients.

Serious or Rare Side Effects: - Gallstone formation: biliary sludge or stones requiring medical attention. - Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain. - Severe allergic reaction: anaphylaxis, angioedema, or urticaria. - Cardiac arrhythmia: irregular heart rhythm observed in rare cases.

Before initiating Lanreotide therapy, several precautionary measures should be considered. - Monitor glucose: lanreotide can alter blood‑sugar levels; regular monitoring is advised. - Assess gallbladder: patients with a history of gallstones should be evaluated due to increased risk. - Evaluate liver function: use with caution in hepatic impairment and adjust therapy as needed. - Watch for hypersensitivity: discontinue immediately if signs of severe allergic reaction appear. - Pregnancy and lactation: safety not established; avoid unless the potential benefit justifies the risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Cyclosporine: may increase lanreotide levels, raising risk of adverse effects. - Octreotide: concurrent use can lead to additive hormonal suppression and higher incidence of gallstones. - Diazoxide: may reduce the therapeutic effect of lanreotide on growth hormone control.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: lanreotide may worsen hyperglycaemia, requiring dose adjustments. - Concomitant somatostatin analogs: increased risk of gastrointestinal side effects and gallstone formation. - Medications affecting gastric emptying: may alter absorption of oral drugs taken with lanreotide.